Group 1 - The core point of the article is that Shanghai Jingxing Industrial Investment Co., Ltd. plans to reduce its stake in Shapuaisi, holding approximately 12.98 million shares, which is about 3.45% of the total share capital, due to funding needs [1] - The planned reduction will occur in two phases: up to approximately 3.76 million shares (1% of total share capital) through centralized bidding from October 10, 2025, to January 9, 2026, and up to approximately 7.52 million shares (2% of total share capital) through block trading during the same period [1] - The total number of shares Shanghai Jingxing plans to reduce is up to approximately 11.28 million shares, which is about 3% of the total share capital [1] Group 2 - For the fiscal year 2024, Shapuaisi's revenue composition is as follows: pharmaceutical industry accounts for 65.74%, diagnostic services for 31.81%, and other businesses for 2.45% [1] - As of the report date, Shapuaisi's market capitalization is 2.9 billion yuan [1]

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-057 浙江莎普爱思药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况： 截至 2025 年 9 月 26 日，上海景兴实业投资有限公司（以下简称"上海景兴"） 持有莎普爱思无限售条件流通股 12,982,726 股，占莎普爱思总股本的 3.4535%。 减持计划的主要内容 上海景兴因资金需求，计划自本公告披露之日起 3 个交易日后的 3 个月内， 即 2025 年 10 月 10 日至 2026 年 1 月 9 日，通过集中竞价交易方式减持的股份 数量不超过 3,759,250 股，即不超过公司总股本的 1.0000%；自公告披露之日起 3 个交易日后至 2026 年 1 月 9 日，通过大宗交易方式减持的股份数量不超过 7,518,500 股，即不超过公司总股本的 2.0000%。上海景兴计划减持数量合计不 超过 11,277,750 股，即不超过公司总股本的 3.0000% ...

格隆汇9月26日丨莎普爱思(603168.SH)公布，上海景兴因资金需求，计划自本公告披露之日起3个交易 日后的3个月内，即2025年10月10日至2026年1月9日，通过集中竞价交易方式减持的股份数量不超过 375.93万股，即不超过公司总股本的1.0000%；自公告披露之日起3个交易日后至2026年1月9日，通过大 宗交易方式减持的股份数量不超过751.85万股，即不超过公司总股本的2.0000%。上海景兴计划减持数 量合计不超过1127.78万股，即不超过公司总股本的3.0000%。 ...

莎普爱思（603168）(603168.SH)发布公告，上海景兴因资金需求，计划自公告披露之日起3个交易日后 的3个月内，即2025年10月10日至2026年1月9日，减持公司股份数量合计不超过1127.78万股，即不超过 公司总股本的3%。 ...

莎普爱思公告，股东上海景兴因个人资金需求，拟自2025年10月10日至2026年1月9日，通过集中竞价和 大宗交易方式合计减持不超过1127.78万股，合计不超过公司总股本的3.0000%。其中，集中竞价方式减 持不超过375.93万股，占1.0000%；大宗交易方式减持不超过751.85万股，占2.0000%。截至2025年9月 26日，上海景兴持股1298.27万股，占3.4535%。 ...

莎普爱思(603168.SH)发布公告，上海景兴因资金需求，计划自公告披露之日起3个交易日后的3个月 内，即2025年10月10日至2026年1月9日，减持公司股份数量合计不超过1127.78万股，即不超过公司总 股本的3%。 ...

Core Viewpoint - As of September 25, a total of 126 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Shandong Publishing, which has seen net buying for 16 consecutive trading days [1] - Other notable stocks with significant net buying days include Dashengda, Guangming Meat, Songlin Technology, Liuhua Co., Tianlong Co., Zhongnan Media, China Merchants Port, and Shapuaisi [1]

Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. announced the postponement of the investment project for the "Phase II Construction Project of Taizhou Women's and Children's Hospital Co., Ltd." to September 30, 2026, due to the cautious implementation of the project and the need to adjust the investment pace [6][9]. Group 1: Board Meeting - The sixth board meeting of Zhejiang Shapuaisi was held on September 24, 2025, with all nine directors present, and the meeting was deemed legal and effective [2][5]. - The board approved the proposal to waive the notification period for the meeting [3]. - The board also approved the proposal regarding the postponement of the fundraising project [3][11]. Group 2: Fundraising Project Details - The company raised a total of approximately RMB 317.99 million through a non-public stock issuance, with a net amount of RMB 308.24 million after deducting various fees [7]. - As of June 30, 2025, the company had used RMB 309.13 million of the raised funds [8]. - The remaining uninvested portion of the project will be funded by the company’s own funds [9][12]. Group 3: Reasons for Postponement - The postponement of the project is attributed to the company's cautious approach in managing its operations and overall fund usage, leading to a slower investment pace [9]. - The decision to extend the project timeline aims to enhance the efficiency of fund utilization [9]. Group 4: Compliance and Opinions - The postponement was reviewed and approved by the board and the audit committee, complying with relevant regulations [11][12]. - The sponsor institution, Shenwan Hongyuan Securities, confirmed that the necessary procedures were followed and had no objections to the postponement [12].

证券日报网讯 9月24日晚间，莎普爱思发布公告称，公司于2025年9月24日召开第六届审计委员会第六 次会议及第六届董事会第十次会议，审议通过了《关于募投项目延期的议案》，同意将非公开发行股票 募投项目"泰州市妇女儿童医院有限公司医院二期建设项目"达到预定可使用状态日期的时间延期至2026 年9月30日。 （编辑 楚丽君） ...

经全体董事逐项审议，通过了如下议案： 1.审议通过《关于豁免第六届董事会第十次会议通知期限的议 案》：全体董事同意豁免公司第六届董事会第十次会议的通知期限，并于2025年9月24日上午召开第六 届董事会第十次会议。表决情况为同意票9票、反对票0票、弃权票0票。 2.审议通过《关于募投项目延 期的议案》：该议案已经公司第六届董事会审计委员会第六次会议审议通过。详细内容可见公司在上海 证券交易所网站（www.sse.com.cn）披露的《关于募投项目延期的公告》（公告编号：临2025 - 056）。表决情况为同意票9票、反对票0票、弃权票0票。 莎普爱思（证券代码：603168，证券简称：莎普爱思）于2025年9月25日发布第六届董事会第十次会议 决议公告。公告显示，公司第六届董事会第十次会议于2025年9月24日上午以通讯方式召开，本次董事 会的召开经全体董事同意豁免会议通知时间要求，会议由董事长林弘立先生主持，应出席董事9人，实 际出席董事9人，公司高级管理人员均知悉本次会议相关情况，会议的召开符合《公司法》和《公司章 程》等有关规定，会议决议合法、有效。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于 ...